Correction: Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats (ACS Nano (2015) 9:5 (4850-4871) DOI: 10.1021/nn506408v);Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats

ACS Nano

Volumn 9, Issue 5, 2015, Pages 4850-4871

  Pahuja, Richa ^a,b,c   Seth, Kavita ^a   Shukla, Anshi ^a   Shukla, Rajendra Kumar ^a   Bhatnagar, Priyanka ^b   Chauhan, Lalit Kumar Singh ^a   Saxena, Prem Narain ^a   Arun, Jharna ^d   Chaudhari, Bhushan Pradosh ^a,c   Patel, Devendra Kumar ^a,c   Singh, Sheelendra Pratap ^a   Shukla, Rakesh ^c,d   Khanna, Vinay Kumar ^a,c   Kumar, Pradeep ^b,c   Chaturvedi, Rajnish Kumar ^a,c   Gupta, Kailash Chand ^a,b,c  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^c ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^d CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

dopamine; nanoparticles; Parkinsons disease; tyrosine hydroxylase

Indexed keywords

AMINO ACIDS; BLOOD; BLOOD PRESSURE; DETERIORATION; DISEASE CONTROL; METABOLITES; NANOPARTICLES; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATION; QUINONE; RATS;

6-HYDROXYDOPAMINE (6-OHDA); DOPAMINE; HEART RATE AND BLOOD PRESSURE; INTRAVENOUS ADMINISTRATION; NEURODEGENERATIVE DISORDERS; PARKINSONS DISEASE; TYROSINE HYDROXYLASE; ULTRASTRUCTURAL CHANGES;

AMINES;

DOPAMINE; DOPAMINE RECEPTOR; DRUG CARRIER; LACTIC ACID; NANOPARTICLE; OXIDOPAMINE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL; BLOOD BRAIN BARRIER; CHEMISTRY; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; DRUG RELEASE; HUMAN; METABOLISM; NEOSTRIATUM; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PATHOPHYSIOLOGY; RAT; SAFETY; TUMOR CELL LINE; UPREGULATION; WISTAR RAT;

ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE, TUMOR; DOPAMINE; DOPAMINERGIC NEURONS; DRUG CARRIERS; DRUG LIBERATION; HUMANS; LACTIC ACID; NANOPARTICLES; NEOSTRIATUM; OXIDATION-REDUCTION; OXIDOPAMINE; PARKINSON DISEASE; POLYGLYCOLIC ACID; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; SAFETY; UP-REGULATION;

EID: 84930641531     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.9b04446     Document Type: Erratum

References (95)

1. Karatas, H.; Aktas, Y.; Gürsoy-Özdemir, Y.; Bodur, E.; Yemişci, M.; Caban, S.; Vural, A.; Pinarbasli, O.; Capan, Y.; Fernandez-Megia, E. et al. A Nanomedicine Transports a Peptide Caspase-3 Inhibitor across the Blood-Brain Barrier and Provides Neuroprotection J. Neurosci. 2009, 29, 13761-13769
2. Yemişci, M.; Gürsoy-Özdemir, Y.; Caban, S.; Bodur, E.; Capan, Y.; Dalkara, T. Transport of a Caspase Inhibitor across the Blood-Brain Barrier by Chitosan Nanoparticles Methods Enzymol. 2012, 508, 253-269
3. Kozlu, S.; Caban, S.; Yerlikaya, F.; Fernandez-Megia, E.; Novoa-Carballal, R.; Riguera, R.; Yemişci, M.; Gürsoy-Özdemir, Y.; Dalkara, T.; Couvreur, P. et al. An Aquaporin 4 Antisense Oligonucleotide Loaded, Brain Targeted Nanoparticulate System Design Pharmazie 2014, 69, 340-345
4. Gazibara, T.; Stankovic, I.; Tomic, A.; Svetel, M.; Tepavcevic, D. K.; Kostic, V. S.; Pekmezovic, T. Validation and Cross-Cultural Adaptation of the Self-Assessment Disability Scale in Patients with Parkinsons Disease in Serbia J. Neurol. 2013, 260, 1970-1977
5. Dauer, W.; Przedborski, S. Parkinsons Disease: Mechanisms and Models Neuron 2003, 39, 889-909
6. Carlsson, T.; Björklund, T. Restoration of the Striatal Dopamine Synthesis for Parkinsons Disease: Viral Vector-Mediated Enzyme Replacement Strategy Curr. Gene Ther. 2007, 7, 109-120
7. Golde, T. E. The Therapeutic Importance of Understanding Mechanisms of Neuronal Cell Death in Neurodegenerative Disease Mol. Neurodegener. 2009, 4, 8
8. Garcia de Yebenes, J.; Fahn, S.; Mena, M. A.; Pardo, B.; Casarejos, M. J. Intracerebroventricular Infusion of Dopamine and Its Agonists in Rodents and Primates. An Experimental Approach to the Treatment of Parkinsons Disease ASAIO Trans. 1988, 34, 951-957
9. Galvan, A.; Floran, B.; Erlij, D.; Aceves, J. Intrapallidal Dopamine Restores Motor Deficits Induced by 6-Hydroxydopamine in the Rat J. Neural Transm. 2001, 108, 153-166
10. Senthilkumar, K. S.; Saravanan, K. S.; Chandra, G.; Sindhu, K. M.; Jayakrishnan, A.; Mohanakumar, K. P. Unilateral Implantation of Dopamine-Loaded Biodegradable Hydrogel in the Striatum Attenuates Motor Abnormalities in the 6-Hydroxydopamine Model of Hemi-Parkinsonism Behav. Brain Res. 2007, 184, 11-18
11. Salat, D.; Tolosa, E. Levodopa in the Treatment of Parkinsons Disease: Current Status and New Developments J. Parkinsons Dis. 2013, 3, 255-269
12. Connolly, B. S.; Lang, A. E. Pharmacological Treatment of Parkinson Disease: A Review JAMA, J. Am. Med. Assoc. 2014, 311, 1670-1683
13. Krishna, R.; Ali, M.; Moustafa, A. A. Effects of Combined MAO-B Inhibitors and Levodopa vs. Monotherapy in Parkinsons Disease Front. Aging Neurosci. 2014, 6, 180
14. Kuwabara, H.; Cumming, P.; Yasuhara, Y.; Léger, G. C.; Guttman, M.; Diksic, M.; Evans, A. C.; Gjedde, A. Regional Striatal DOPA Transport and Decarboxylase Activity in Parkinsons Disease J. Nucl. Med. 1995, 36, 1226-1231
15. DAurizio, E.; Sozio, P.; Cerasa, L. S.; Vacca, M.; Brunetti, L.; Orlando, G.; Chiavaroli, A.; Kok, R. J.; Hennink, W. E.; Di Stefano, A. Biodegradable Microspheres Loaded with an Anti-Parkinson Prodrug: An in Vivo Pharmacokinetic Study Mol. Pharmaceutics 2011, 8, 2408-2415
16. Ren, T.; Yang, X.; Wu, N.; Cai, Y.; Liu, Z.; Yuan, W. Sustained-Release Formulation of Levodopa Methyl Ester/Benserazide for Prolonged Suppressing Dyskinesia Expression in 6-OHDA-Leisoned Rats Neurosci. Lett. 2011, 502, 117-122
17. Wang, A.; Wang, L.; Sun, K.; Liu, W.; Sha, C.; Li, Y. Preparation of Rotigotine-Loaded Microspheres and their Combination Use with l -DOPA to Modify Dyskinesias in 6-OHDA-Lesioned Rats Pharm. Res. 2012, 29, 2367-2376
18. Regnier-Delplace, C.; Thillaye du Boullay, O.; Siepmann, F.; Martin-Vaca, B.; Degrave, N.; Demonchaux, P.; Jentzer, O.; Bourissou, D.; Siepmann, J. PLGA Microparticles with Zero-Order Release of the Labile Anti-Parkinson Drug Apomorphine Int. J. Pharm. 2013, 443, 68-79
19. Wright, B. A.; Waters, C. H. Continuous Dopaminergic Delivery to Minimize Motor Complications in Parkinsons Disease Expert Rev. Neurother. 2013, 13, 719-729
20. Carlsson, T.; Winkler, C.; Burger, C.; Muzyczka, N.; Mandel, R. J.; Cenci, A.; Björklund, A.; Kirik, D. Reversal of Dyskinesias in an Animal Model of Parkinsons Disease by Continuous l -DOPA Delivery Using rAAV Vectors Brain 2005, 128, 559-569
21. Pellicano, C.; Benincasa, D.; Fanciulli, A.; Latino, P.; Giovannelli, M.; Pontieri, F. E. The Impact of Extended Release Dopamine Agonists on Prescribing Patterns for Therapy of Early Parkinsons Disease: An Observational Study Eur. J. Med. Res. 2013, 18-60
22. 2-Dopamine Complex Implanted Unilaterally in the Caudate Nucleus Improves Motor Activity and Behavior Function of Rats with Induced Hemiparkinsonism Proc. West Pharmacol. Soc. 2011, 54, 15-20
23. Tiwari, S. K.; Agarwal, S.; Seth, B.; Yadav, A.; Nair, S.; Bhatnagar, P.; Karmakar, M.; Kumari, M.; Chauhan, L. K. S.; Patel, D. K. et al. Curcumin-Loaded Nanoparticles Potently Induce Adult Neurogenesis and Reverse Cognitive Deficits in Alzheimers Disease Model via Canonical Wnt/β-Catenin Pathway ACS Nano 2014, 8, 76-103
24. Jose, S.; Sowmya, S.; Cinu, T. A.; Aleykutty, N. A.; Thomas, S.; Souto, E. B. Surface Modified PLGA Nanoparticles for Brain Targeting of Bacoside-A Eur. J. Pharm. Sci. 2014, 63, 29-35
25. Tiwari, M. N.; Agarwal, S.; Bhatnagar, P.; Singhal, N. K.; Tiwari, S. K.; Kumar, P.; Chauhan, L. K.; Patel, D. K.; Chaturvedi, R. K.; Singh, M. P. et al. Nicotine-Encapsulated Poly(lactic-co-glycolic) Acid Nanoparticles Improve Neuroprotective Efficacy against MPTP-Induced Parkinsonism Free Radical Biol. Med. 2013, 65, 704-718
26. Hu, K.; Shi, Y.; Jiang, W.; Han, J.; Huang, S.; Jiang, X. Lactoferrin Conjugated PEG-PLGA Nanoparticles for Brain Delivery: Preparation, Characterization and Efficacy in Parkinsons Disease Int. J. Pharm. 2011, 415, 273-283
27. Herrán, E.; Requejo, C.; Ruiz-Ortega, J. A.; Aristieta, A.; Igartua, M.; Bengoetxea, H.; Ugedo, L.; Pedraz, J. L.; Lafuente, J. V.; Hernández, R. M. Increased Antiparkinson Efficacy of the Combined Administration of VEGF- and GDNF-Loaded Nanospheres in a Partial Lesion Model of Parkinsons Disease Int. J. Nanomed. 2014, 9, 2677-2687
28. Bissonnette, B.; Sims, C. Resuscitation Agents Pediatr. Anesth.-Basic Principles, State Art, Future 2011, 552-570
29. Lankveld, D. P.; Oomen, A. G.; Krystek, P.; Neigh, A.; Troost-de Jong, A.; Noorlander, C. W.; Van Eijkeren, J. C.; Geertsma, R. E.; De Jong, W. H. The Kinetics of the Tissue Distribution of Silver Nanoparticles of Different Sizes Biomaterials 2010, 31, 8350-8361
30. Unsoy, G.; Khodadust, R.; Yalcin, S.; Mutlu, P.; Gunduz, U. Synthesis of Doxorubicin Loaded Magnetic Chitosan Nanoparticles for pH Responsive Targeted Drug Delivery Eur. J. Pharm. Sci. 2014, 62, 243-250
31. Zolnik, B. S.; Burgess, D. J. Effect of Acidic pH on PLGA Microsphere Degradation and Release J. Controlled Release 2007, 122, 338-434
32. Faisant, N.; Siepmann, J.; Benoit, J. P. PLGA-Based Microparticles: Elucidation of Mechanisms and a New, Simple Mathematical Model Quantifying Drug Release Eur. J. Pharm. Sci. 2002, 15, 355-366
33. Lazzari, S.; Moscatelli, D.; Codari, F.; Salmona, M.; Morbidelli, M.; Diomede, L. Colloidal Stability of Polymeric Nanoparticles in Biological Fluids J. Nanopart. Res. 2012, 14, 920-929
34. Wang, H.; Zhao, Y.; Wua, Y.; Hub, Y.; Nan, K.; Nie, G.; Chen, H. Enhanced Anti-Tumor Efficacy by Co-delivery of Doxorubicin and Paclitaxel with Amphiphilic Methoxy PEG-PLGA Copolymer Nanoparticles Biomaterials 2011, 32, 8281-8290
35. Nevesa, J.; Amijic, M.; Bahiab, M. F.; Sarmento, B. Assessing the Physical-Chemical Properties and Stability of Dapivirine-Loaded Polymeric Nanoparticles Int. J. Pharm. 2013, 456, 307-314
36. Bisaglia, M.; Mammi, S.; Bubacco, L. Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine: Analysis of the Interactions with Alpha-Synuclein J. Biol. Chem. 2007, 282, 15597-15605
37. Witkovsky, P.; Patel, J. C.; Lee, C. R.; Rice, M. E. Immunocytochemical Identification of Proteins Involved in Dopamine Release from the Somatodendritic Compartment of Nigral Dopaminergic Neurons Neuroscience 2009, 164, 488-496
38. Sotnikova, T. D.; Beaulieu, J. M.; Gainetdinov, R. R.; Caron, M. G. Molecular Biology, Pharmacology and Functional Role of the Plasma Membrane Dopamine Transporter CNS Neurol. Disord. Drug Targets 2006, 5, 45-56
39. Nirenberg, M. J.; Vaughan, R. A.; Uhl, G. R.; Kuhar, M. J.; PickelI, V. M. The Dopamine Transporter Is Localized to Dendritic and Axonal Plasma Membranes of Nigrostriatal Dopaminergic Neurons J. Neurosci. 1996, 76, 436-447
40. Eriksen, J.; Rasmussen, S. G. F.; Rasmussen, T. N.; Vaegter, C. B.; Cha, J. H.; Zou, M.; Newman, A. H.; Gether, U. Visualization of Dopamine Transporter Trafficking in Live Neurons by Use of Fluorescent Cocaine Analogs J. Neurosci. 2009, 29, 6794-6808
41. Pickel, V. M.; Chan, J.; Nirenberg, M. J. Region-Specific Targeting of Dopamine D2-Receptors and Somatodendritic Vesicular Monoamine Transporter 2 (VMAT2) within Ventral Tegmental Area Subdivisions Synapse 2002, 45, 113-124
42. Xu, P.; Gullotti, E.; Tong, L.; Highley, C. B.; Errabelli, D. R.; Hasan, T.; Cheng, J. X.; Kohane, D. S.; Ye, Y. Intracellular Drug Delivery by Poly(lactic-co-glycolic acid) Nanoparticles, Revisited Mol. Pharmaceutics 2009, 6, 190-201
43. Park, I. K.; Lasiene, J.; Chou, S. H.; Horner, P. J.; Pun, S. H. Neuron-Specific Delivery of Nucleic Acids Mediated by Tet1-Modified Poly(ethylenimine) J. Gene Med. 2007, 9, 691-702
44. Singhal, A.; Morris, V. B.; Labhasetwar, V.; Ghorpade, A. Nanoparticle-Mediated Catalase Delivery Protects Human Neurons from Oxidative Stress Cell Death Dis. 2013, 4, e903
45. Jiang, Y.; Pei, L.; Li, S.; Wang, M.; Liu, F. Extracellular Dopamine Induces the Oxidative Toxicity of SH-SY5Y Cells Synapse 2008, 62, 797-803
46. Asanuma, M.; Miyazaki, I.; Ogawa, N. Dopamine- or L-DOPA-Induced Neurotoxicity: The Role of Dopamine Quinone Formation and Tyrosinase in a Model of Parkinsons Disease Neurotox. Res. 2003, 5, 165-176
47. Asanuma, M.; Miyazaki, I.; Diaz-Corrales, F. J.; Ogawa, N. Quinone Formation as Dopaminergic Neuron-Specific Oxidative Stress in the Pathogenesis of Sporadic Parkinsons Disease and Neurotoxin-Induced Parkinsonism Acta Med. Okayama 2004, 58, 221-233
48. Kura, A. U.; Ain, N. M.; Hussein, M. Z.; Fakurazi, S.; Hussein-Al-Ali, S. H. Toxicity and Metabolism of Layered Double Hydroxide Intercalated with Levodopa in a Parkinsons Disease Model Int. J. Mol. Sci. 2014, 15, 5916-5927
49. Tan, J. M.; Foo, J. B.; Fakurazi, S.; Hussein, M. Z. Release Behaviour and Toxicity Evaluation of Levodopa from Carboxylated Single-Walled Carbon Nanotubes Beilstein J. Nanotechnol. 2015, 6, 243-253
50. Ham, A.; Lee, S. J.; Shin, J.; Kim, K. H.; Mar, W. Regulatory Effects of Costunolide on Dopamine Metabolism-Associated Genes Inhibit Dopamine-Induced Apoptosis in Human Dopaminergic SH-SY5Y Cells Neurosci. Lett. 2012, 507, 101-105
51. Koshimura, K.; Tanaka, J.; Murakami, Y.; Kato, Y. Effects of Dopamine and L-DOPA on Survival of PC12 Cells J. Neurosci Res. 2000, 62, 112-119
52. Kawashima, T.; Ohkubo, K.; Fukuzumi, S. Radical Scavenging Reactivity of Catecholamine Neurotransmitters and the Inhibition Effect for DNA Cleavage J. Phys. Chem. B 2010, 114, 675-680
53. OKeeffe, G. C.; Barker, R. A.; Caldwell, M. A. Dopaminergic Modulation of Neurogenesis in the Subventricular Zone of the Adult Brain Cell Cycle 2009, 8, 2888-2894
54. OKeeffe, G. C.; Tyers, P.; Aarsland, D.; Dalley, J. W.; Barker, R. A.; Caldwell, M. A. Dopamine-Induced Proliferation of Adult Neural Precursor Cells in the Mammalian Subventricular Zone is Mediated through EGF Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 8754-8759
55. Höglinger, G.; Rizk, P.; Muriel, M. P.; Duyckaerts, C.; Oertel, W. H.; Caille, I.; Hirsch, E. C. Dopamine Depletion Impairs Precursor Cell Proliferation in Parkinson Disease Nat. Neurosci. 2004, 7, 726-735
56. Chaturvedi, R. K.; Shukla, S.; Seth, K.; Agrawal, A. K. Zuckerkandls Organ Improves Long-Term Survival and Function of Neural Stem Cell Derived Dopaminergic Neurons in Parkinsonian Rats Exp. Neurol. 2008, 210, 608-623
57. Bisaglia, M.; Soriano, M. E.; Arduini, I.; Mammi, S.; Bubacco, L. Molecular Characterization of Dopamine-Derived Quinones Reactivity toward NADH and Glutathione: Implications for Mitochondrial Dysfunction in Parkinson Disease Biochim. Biophys. Acta 2010, 1802, 699-706
58. Belluzzi, E.; Bisaglia, M.; Lazzarini, E.; Tabares, L. C.; Beltramini, M.; Bubacco, L. Human SOD2 Modification by Dopamine Quinones Affects Enzymatic Activity by Promoting Its Aggregation: Possible Implications for Parkinsons Disease PLoS One 2012, 7, e38026
59. Vermeer, L. M.; Florang, V. R.; Doorn, J. A. Catechol and Aldehyde Moieties of 3,4-Dihydroxyphenylacetaldehyde Contribute to Tyrosine Hydroxylase Inhibition and Neurotoxicity Brain Res. 2012, 1474, 100-109
60. Brunelle, J. K.; Letai, A. Control of Mitochondrial Apoptosis by the Bcl-2 Family J. Cell Sci. 2009, 122, 437-441
61. DHerde, K.; De Prest, B.; Mussche, S.; Schotte, P.; Beyaert, R.; Coster, R. V.; Roels, F. Ultrastructural Localization of Cytochrome C in Apoptosis Demonstrates Mitochondrial Heterogeneity Cell Death Differ. 2000, 7, 331-337
62. Tait, S. W.; Green, D. R. Mitochondria and Cell Death: Outer Membrane Permeabilization and Beyond Nat. Rev. Mol. Cell Biol. 2010, 11, 621-632
63. Kang, C. D.; Jang, J. H.; Kim, K. W.; Lee, H. J.; Jeong, C. S.; Kim, C. M.; Kim, S. H.; Chung, B. S. Activation of c-jun N-Terminal Kinase/Stress-Activated Protein Kinase and the Decreased Ratio of Bcl-2 to Bax Are Associated with the Auto-Oxidized Dopamine-Induced Apoptosis in PC12 Cells Neurosci. Lett. 1998, 256, 37-40
64. van der Heide, L. P.; Smidt, M. P. The BCL2 Code to Dopaminergic Development and Parkinsons Disease Trends Mol. Med. 2013, 19, 211-216
65. Wang, D. B.; Kinoshita, C.; Kinoshita, Y.; Morrison, R. S. p53 and Mitochondrial Function in Neurons Biochim. Biophys. Acta 2014, 1842, 1186-1197
66. Jeon, S. M.; Cheon, S. M.; Bae, H. R.; Kim, J. W.; Kim, S. U. Selective Susceptibility of Human Dopaminergic Neural Stem Cells to Dopamine-Induced Apoptosis Exp. Neurobiol. 2010, 19, 155-164
67. Parrot, S.; Neuzeret, P. C.; Denoroy, L. A Rapid and Sensitive Method for the Analysis of Brain Monoamine Neurotransmitters Using Ultra-fast Liquidchromatography Coupled to Electrochemical Detection J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2011, 879, 3871-3878
68. Gambaryan, P. Y.; Kondrasheva, I. G.; Severin, E. S.; Guseva, A. A.; Kamensky, A. A. Increasing the Efficiency of Parkinsons Disease Treatment Using a Poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System Exp. Neurobiol. 2014, 23, 246-252
69. Trapani, A.; De Giglio, E.; Cafagna, D.; Denora, N.; Agrimi, G.; Cassano, T.; Gaetani, S.; Cuomo, V.; Trapani, G. Characterization and Evaluation of Chitosan Nanoparticles for Dopamine Brain Delivery Int. J. Pharm. 2011, 419, 296-307
70. Asanuma, M.; Miyazaki, I.; Murakami, S.; Diaz-Corrales, F. J.; Ogawa, N. Striatal Astrocytes Act as a Reservoir for L-DOPA PLoS One 2014, 9, e106362
71. Shukla, S.; Chaturvedi, R. K.; Seth, K.; Roy, N. S.; Agrawal, A. K. Enhanced Survival and Function of Neural Stem Cells-Derived Dopaminergic Neurons under Influence of Olfactory Ensheathing Cells in Parkinsonian Rats J. Neurochem. 2009, 109, 436-451
72. Woiciechowsky, C.; Guilarte, T. R.; May, C. H.; Vesper, J.; Wagner, H. N., Jr.; Vogel, S. Intrastriatal Dopamine Infusion Reverses Compensatory Increases in D2-Dopamine Receptors in the 6-OHDA Lesioned Rat Neurodegeneration 1995, 4, 161-169
73. Wei, W.; Li, L.; Yu, G.; Ding, S.; Li, C.; Zhou, F. M. Supersensitive Presynaptic Dopamine D2 Receptor Inhibition of the Striatopallidal Projection in Nigrostriatal Dopamine-Deficient Mice J. Neurophysiol. 2013, 110, 2203-2216
74. Scherfler, C.; Khan, N. L.; Pavese, N.; Lees, A. J.; Quinn, N. P.; Brooks, D. J.; Piccini, P. P. Upregulation of Dopamine D2 Receptors in Dopaminergic Drug-Naive Patients with Parkin Gene Mutations Mov. Disord. 2006, 21, 783-788
75. Sahin, G.; Thompson, L. H.; Lavisse, S.; Ozgur, M.; Rbah-Vidal, L.; Dollé, F.; Hantraye, P.; Kirik, D. Differential Dopamine Receptor Occupancy Underlies L-DOPA-Induced Dyskinesia in a Rat Model of Parkinsons Disease PLoS One 2014, 9, e90759
76. Chaturvedi, R. K.; Shukla, S.; Seth, K.; Agrawal, A. K. Nerve Growth Factor Increases Survival of Dopaminergic Graft, Rescue Nigral Dopaminergic Neurons and Restores Functional Deficits in Rat Model of Parkinsons Disease Neurosci. Lett. 2006, 398, 44-49
77. Yang, X.; Zheng, R.; Cai, Y.; Liao, M.; Yuan, W.; Liu, Z. Controlled-Release Levodopa Methyl Ester/Benserazide-Loaded Nanoparticles Ameliorate Levodopa-Induced Dyskinesia in Rats Int. J. Nanomedicine 2012, 7, 2077-2086
78. Wang, N.; Wang, Y.; Yu, G.; Yuan, C.; Ma, J. Quinoprotein Adducts Accumulate in the Substantia Nigra of Aged Rats and Correlate with Dopamine-Induced Toxicity in SH-SY5Y Cells Neurochem. Res. 2011, 36, 2169-2175
79. Lach, B.; Grimes, D.; Benoit, B.; Janda, A. M. Caudate Nucleus Pathology in Parkinsons Disease: Ultrastructural and Biochemical Findings in Biopsy Material Acta Neuropathol. 1992, 83, 352-360
80. Gutierrez-Valdez, A. L.; Anaya-Martínez, V.; Ordoñez-Librado, J. L.; García-Ruiz, R.; Torres-Esquivel, C.; Moreno-Rivera, M.; Sánchez-Betancourt, J.; Montiel-Flores, E.; Avila-Costa, M. R. Effect of Chronic L-Dopa or Melatonin Treatments after Dopamine Deafferentation in Rats: Dyskinesia, Motor Performance, and Cytological Analysis ISRN Neurol. 2012, 2012, e360379
81. Shin, M.; Kim, H. K.; Lee, H. Dopamine-Loaded Poly(D,L-lactic-co-glycolic acid) Microspheres: New Strategy for Encapsulating Small Hydrophilic Drugs with High Efficiency Biotechnol. Prog. 2014, 30, 215-223
82. Swami, A.; Aggarwal, A.; Pathak, A.; Patnaik, S.; Kumar, P.; Singh, Y.; Gupta, K. C. Imidazolyl-Pei Modified Nanoparticles for Enhanced Gene Delivery Int. J. Pharm. 2007, 335, 180-192
83. Wang, F.; Franco, R.; Skotak, M.; Hu, G.; Chandra, N. Mechanical Stretch Exacerbates the Cell Death in SH-SY5Y Cells Exposed to Paraquat: Mitochondrial Dysfunction and Oxidative Stress Neurotoxicology 2014, 14, 54-63
84. Shukla, A.; Mohapatra, T. M.; Parmar, D.; Seth, K. Neuroprotective Potentials of Neurotrophin Rich Olfactory Ensheathing Cells Conditioned Media against 6OHDA-Induced Oxidative Damage Free Radical Res. 2014, 48, 560-571
85. Shukla, A.; Mohapatra, T. M.; Agrawal, A. K.; Parmar, D.; Seth, K. Salsolinol Induced Apoptotic Changes in Neural Stem Cells: Amelioration by Neurotrophin Support Neurotoxicology 2013, 35, 50-61
86. Agrawal, A. K.; Shukla, S.; Chaturvedi, R. K.; Seth, K.; Srivastava, N.; Ahmad, A.; Seth, P. K. Olfactory Ensheathing Cell Transplantation Restores Functional Deficits in Rat Model of Parkinsons Disease: A Cotransplantation Approach with Fetal Ventral Mesencephalic Cells Neurobiol. Dis. 2004, 16, 516-526
87. Paxinos, G.; Watson, C. The Rat Brain in Stereotaxic Coordinates, 4 th ed; Academic Press: CA, 1998.
88. Sundaram, S.; Roy, S. K.; Ambati, B. K.; Kompella, U. B. Surface-Functionalized Nanoparticles for Targeted Gene Delivery across Nasal Respiratory Epithelium FASEB J. 2009, 23, 3752-3765
89. Yadav, R. S.; Sankhwar, M. L.; Shukla, R. K.; Chandra, R.; Pant, A. B.; Islam, F.; Khanna, V. K. Attenuation of Arsenic Neurotoxicity by Curcumin in Rats Toxicol. Appl. Pharmacol. 2009, 240, 367-376
90. Wood, P. L.; Kim, H. S.; Marien, M. R. Intracerebral Dialysis: Direct Evidence for the Utility of 3-MT Measurements as an Index of Dopamine Release Life Sci. 1987, 41, 1-5
91. Miyazaki, I.; Asanuma, M.; Kikkawa, Y.; Takeshima, M.; Murakami, S.; Miyoshi, K.; Sogawa, N.; Kita, T. Astrocyte-Derived Metallothionein Protects Dopaminergic Neurons from Dopamine Quinone Toxicity Glia 2011, 59, 435-451
92. Panigrahi, G.; Tiwari, S.; Ansari, K. M.; Chaturvedi, R. K.; Khanna, V. K.; Chaudhari, B. P.; Vashistha, V. M.; Raisuddin, S.; Das, M. Association between Children Death and Consumption of Cassia occidentalis Seeds: Clinical and Experimental Investigations Food Chem. Toxicol. 2014, 67, 236-248
93. Zhu, Y. Z.; Zhu, Y. C.; Li, J.; Schäfer, H.; Schmidt, W.; Yao, T.; Unger, T. Effects of Losartan on Haemodynamic Parameters and Angiotensin Receptor mRNA Levels in Rat Heart after Myocardial Infarction J. Renin Angiotensin Aldosterone Syst. 2000, 1, 257-262
94. Perez-Olea, J.; Quevedo, M.; Silva, R. Enhancement of Blood Pressure Response to Dopamine by Angiotensin II Hypertension 1981, 3, 138-141
95. Midgley, A. C.; Mathew, R.; Hallett, M. B.; Clayton, A.; Bowen, T.; Phillips, A. O.; Steadman, R. Transforming Growth Factor-β1 (TGF-β1)-Stimulated Fibroblast to Myofibroblast Differentiation Is Mediated by Hyaluronan (HA)-Facilitated Epidermal Growth Factor Receptor (EGFR) and CD44 Co-localization in Lipid Rafts J. Biol. Chem. 2013, 288, 14824-14838